SCHEDULE 13G: Adage Capital Management Discloses 6.43% Stake in Amylyx Pharmaceuticals
Beneficial Ownership Disclosure
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 6.43% beneficial ownership stake in Amylyx Pharmaceuticals, Inc., totaling 5,697,605 shares of common stock.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 5,697,605 shares of Amylyx Pharmaceuticals, Inc. common stock.
- This ownership represents 6.43% of Amylyx Pharmaceuticals, Inc.'s outstanding common stock.
- The percentage is calculated based on 88,602,468 shares of common stock outstanding as of February 28, 2025, as reported in the company's Annual Report on Form 10-K.
- The reporting persons, including Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross, hold these shares in the ordinary course of business.
- The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Amylyx Pharmaceuticals, Inc.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a significant institutional ownership stake. While not directly financial performance news, the disclosure of a 6.43% stake by a reputable investment firm like Adage Capital Management can be perceived as a positive signal of investor confidence in Amylyx Pharmaceuticals.
Positives
- A notable institutional investor, Adage Capital Management, L.P., has disclosed a significant stake of 6.43% in Amylyx Pharmaceuticals, Inc., which can be interpreted as a vote of confidence in the company's prospects.
Negatives
- NA
Risks
- The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, mitigating concerns about potential activist investor actions.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Amylyx Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common for publicly traded companies as large investment firms build or adjust their positions, providing transparency on major ownership stakes.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor sentiment positively due to a large, reputable firm taking a substantial stake.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Amylyx Pharmaceuticals, Inc., as reported in their Annual Report on Form 10-K. |
| 2025-02-28 | Date as of which 88,602,468 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-03-04 | Date Amylyx Pharmaceuticals, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership exceeding 5%). |
| 2025-05-12 | Date of filing of this Schedule 13G statement. |
Keywords
Amylyx Pharmaceuticals, Adage Capital Management, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.